Download a complete bibliography from each of our ongoing investigational programs below.
SPR206
Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter spp. Causing Infections in Europe and Adjacent Regions
SPR206
In Vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in Hospitals in Europe and Adjacent Regions
Tebipenem HBR
Clinical and microbiological outcomes for Enterobacterales uropathogens in the Phase 3 ADAPT-PO Study of oral tebipenem pivoxil hydrobromide
SPR206
SPR206 Pharmacokinetics (PK) in Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Adult Subjects
Enterobacterales Resistance Patterns for Extended Spectrum β lactamase (ESBL) Positive and Multidrug Resistant (MDR) Urine Isolates Collected and Tested from 295 Outpatient US Facilities in 2019
Tebipenem HBR
Effectiveness of TBP PI HBr in Patients with Instrumentation, Anatomic or Functional Abnormalities: Secondary Analysis from ADAPT PO
The Economic Burden of Adverse Events Requiring Acute Care Service from Outpatient Parenteral Antibiotic Treatment (OPAT)
Tebipenem HBR
Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study. BMC Infect Dis. 2021 Feb 8;21(1):159.
SPR206
Zabawa TP, Pucci MJ, Parr TR Jr, Lister T. Treatment of Gram-negative bacterial infections by potentiation of antibiotics. Curr Opin Microbiol. 2016 Oct;33:7-12.
SPR741
Zurawski DV, Reinhart AA, Alamneh YA, et al. SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01239-17.
Tebipenem HBR
Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Antimicrobial Susceptibility and Cross-Resistance Patterns among Common Complicated Urinary Tract Infections in U.S. Hospitals, 2013 to 2018. Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00346-20.
SPR206
Understanding the SAR interplay for kidney exposure and cytotoxicity facilitates the design of improved polymyxin derivatives – identification of SPR206 as a development candidate
SPR720
Treatment of Mycobacterium avium subspecies hominissuis (MAH) infection with a novel gyrase inhibitor (SPR719/SPR720) was associated with a significant decrease in bacterial load as assessed in macrophages, biofilm and in mice
Tebipenem HBR
Tebipenem: An oral carbapenem with activity against multi-drug resistant urinary tract infection isolates of Escherichia coli collected from US medical centers during 2019
SPR206
The impact of varied test conditions on the in vitro activity of SPR206, a next-generation polymyxin B analog, against drug-susceptible and multidrug-resistant gram-negative pathogens
Thomas J, Navre M, Rubio A, Coukell A. Shared Platform for Antibiotic Research and Knowledge: A Collaborative Tool to SPARK Antibiotic Discovery. ACS Infect Dis. 2018 Nov 9;4(11):1536-1539.
Tebipenem HBR
The impact of antibiotic resistance on hospitalized patients with Enterobacteriaceae (ENT) urinary tract infections (UTI): a multicenter analysis
Tebipenem HBR
The 30-day economic burden of newly diagnosed complicated urinary tract infections in Medicare patients.
Tebipenem HBR
The burden of resistance among urinary tract isolates of Escherichia coli in the United States in 2017
Tebipenem HBR
Lodise T, Nowak M, Rodriguez M. The 30-Day Economic Burden of Newly Diagnosed Complicated Urinary Tract Infections in Medicare Fee-for-Service Patients Who Resided in the Community. Antibiotics 2022; 11(5):578.
Tebipenem HBR
Tebipenem pivoxil hydrobromide: Safety and tolerability profile of the first oral carbapenem for complicated urinary tract infection and acute pyelonephritis
Tebipenem HBR
Tebipenem in vitro activity against a collection of pathogens responsible for urinary tract infections in the US
Tebipenem HBR
In vitro activity of tebipenem against clinically significant gram-negative bacteria isolated from patients with cancer
Tebipenem HBR
Tebipenem: An oral carbapenem with activity against multi-drug resistant urinary tract infection isolates of Escherichia coli collected from US medical centers during 2019
SPR720
Talley AK, Thurston A, Moore G, et al. First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. Antimicrob Agents Chemother. 2021 Sep 7:AAC0120821.
SPR720
Stokes SS, Vemula R, Pucci MJ. Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. ACS Infect Dis. 2020 Jun 12;6(6):1323-1331.
SPR741
SPR741 in combination with minocycline increases antibacterial efficacy in vitro and in vivo against XDR-Acinetobacter baumannii in a pulmonary model of infection
SPR741
Safety of SPR741, a novel polymyxin potentiator, in healthy adults receiving single- and multiple-dose intravenous administrations
SPR741
Stainton SM, Abdelraouf K, Utley L, et al. Assessment of the In Vivo Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00239-18.
Tebipenem HBR
SPR994: oral carbapenem for the treatment of complicated urinary tract infections
Tebipenem HBR
Patient demographics and comorbidity profiles associated with hospitalized patients admitted with resistant versus susceptible urinary tract infections (UTI): a multicenter analysis
Tebipenem HBR
SPR994 (oral carbapenem prodrug): what’s in the pipeline?
SPR720
SPR720: novel oral therapy for non-tuberculous Mycobacterial (NTM) infections
Tebipenem HBR
Single- and multiple-ascending dose (SAD/MAD) study demonstrates the human pharmacokinetics (PK) and tolerability of SPR994 (tebipenem pivoxil hydrobromide), an oral carbapenem (CP), at the predicted therapeutic dose
Tebipenem HBR
Single-and multiple-ascending dose (SAD/MAD) study demonstrates the human pharmacokinetics (PK) and tolerability of SPR994 (tebipenem pivoxil hydrobromide), an oral carbapenem (CP), at the predicted therapeutic dose
SPR720
SPR720, a novel aminobenzimidazole gyrase inhibitor, demonstrates potent efficacy against Mycobacterium avium ATCC 700898 in a chronic C3HeBFeJ mouse infection model
Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clin Infect Dis. 2017 Jul 1;65(1):141-146.
Tebipenem HBR
Rubio A, Pucci MJ, Jain A. Characterization of SPR994, an orally available carbapenem, with activity comparable to intravenously administered carbapenems. ACS Infect Dis. 2018 Oct 12;4(10):1436-1438.
Tebipenem HBR
Resistance to oral antibiotics among urinary tract infection isolates of Escherichia coli from the United States and Europe in 2017
Tebipenem HBR
Relationship between receipt of prior antibiotics and presence of antibiotic resistance among adult outpatients with complicated urinary tract infection
Tebipenem HBR
Pre and post hospitalization resource utilization and costs associated with urinary tract infection (UTI) in both commercial and Medicare populations
Pucci MJ, Dougherty TJ. Editorial overview: Antimicrobials: fighting bacterial infections in the 21st century-thinking outside of the box. Curr Opin Microbiol. 2016 Oct;33:v-vii
Tebipenem HBR
Plasma pharmacokinetics and intrapulmonary penetration of tebipenem in healthy subjects
Tebipenem HBR
Population pharmacokinetic analyses for tebipenem after the administration of tebipenem pivoxil hydrobromide
SPR720
Potent activity of a novel gyrase inhibitor (SPR719/SPR720) in vitro and in a prolonged acute Mycobacterium abscessus mouse model of infection
SPR720
Pidot SJ, Porter JL, Lister T, Stinear TP. In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl Trop Dis. 2021 Jul 26;15(7):e0009636.
SPR720
Phase 1 first-in-human single-and multiple-ascending dose trial demonstrates pharmacokinetics and tolerability of SPR720, an oral DNA GyrB inhibitor for Mycobacterial infections
SPR720
Pharmacokinetics/pharmacodynamics of the novel gyrase inhibitor SPR719/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium complex disease
Tebipenem HBR
Patel G, Rodvold KA, Gupta VK, et al. Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment. Antimicrob Agents Chemother. 2022 Apr 14. doi: 10.1128/aac.02407-21. Epub ahead of print.
Unable to find what you were looking for?
Download a complete bibliography from each of our ongoing investigational programs below.
